Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Biosimilar Naming Proposal Pits Providers, Patients Against Insurers, Pharmacies

Executive Summary

Suffix-based, distinguishable names cheered by physicians and patient advocacy groups as enhancing patient safety; payers and pharmacists object, saying plan adds unneeded complexity and will require expensive overhauls in databases and operating systems.

Advertisement

Related Content

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Topics

Advertisement
UsernamePublicRestriction

Register

PS057268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel